P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)

التفاصيل البيبلوغرافية
العنوان:	P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
المؤلفون:	V. Gupta, A. Yacoub, S. Verstovsek, R. A. Mesa, C. N. Harrison, G. Barosi, J.-J. Kiladjian, H. J. Deeg, S. Fazal, L. Foltz, R. J. Mattison, C. B. Miller, V. Parameswaran, C. Hernandez, J. Zhang, M. Talpaz
المصدر:	HemaSphere, Vol 6, Pp 932-933 (2022)
بيانات النشر:	Wiley, 2022.
سنة النشر:	2022
المجموعة:	LCC:Diseases of the blood and blood-forming organs
مصطلحات موضوعية:	Diseases of the blood and blood-forming organs, RC633-647.5
نوع الوثيقة:	article
وصف الملف:	electronic resource
اللغة:	English
تدمد:	2572-9241
Relation:	http://journals.lww.com/10.1097/01.HS9.0000847036.30498.e9; https://doaj.org/toc/2572-9241
DOI:	10.1097/01.HS9.0000847036.30498.e9
URL الوصول:	https://doaj.org/article/9b130111bda04504abc385df767fd3d6
رقم الأكسشن:	edsdoj.9b130111bda04504abc385df767fd3d6
قاعدة البيانات:	Directory of Open Access Journals

الوصف
تدمد:	25729241
DOI:	10.1097/01.HS9.0000847036.30498.e9